David Marcus
Managing Director, Life Sciences
Get their honest, personalized take on your startup.
Sign in to pitch David →At a glance
- Full Name
- David Marcus
- Title
- Managing Director, Life Sciences
- Firm
- VIMAC Ventures LLC (life-sciences investing via the VIMAC Milestone Medica Fund)
- Firm Type
- Venture capital firm (early-stage life sciences). *Note: the original stub labeled him an "Angel Investor / Seed Round," but VIMAC's life-sciences arm operates as an institutional early-stage fund rather than a personal angel vehicle.*
- Investment Stage
- Early stage — typically enters at the first institutional round (Series A / Series B)
- Check Size
- Approximately $5M–$15M invested per company over its life (initial round plus reserves for follow-on)
- Target Company Profile
- Early-stage biotechnology and medical-device companies, usually raising their first institutional round; VIMAC leads or co-leads and takes an active board role
- Sector Focus
- Life sciences — biotechnology, pharmaceuticals, and medical devices
- Geographic Focus
- United States and Canada (firm based in Boston, MA)
- Location
- Newton, Massachusetts, USA
Background
David Marcus is Managing Director for Life Sciences at VIMAC Ventures LLC, a Boston-based venture capital firm founded in 1982 that invests across information technology / advanced materials and life sciences through two separate investment teams. Marcus leads the life-sciences side, which deploys capital through the VIMAC Milestone Medica Fund into early-stage biotechnology and medical-device companies. He is based in Newton, Massachusetts.
According to aggregator profiles (ZoomInfo, RocketReach, Bloomberg), before VIMAC Marcus co-founded Wellfleet Investments, and he holds a Bachelor's degree from Syracuse University. His stated areas of expertise include startups, business strategy, management, entrepreneurship, and due diligence — consistent with a hands-on, board-level investor rather than a passive capital source.
VIMAC's life-sciences fund, VIMAC Milestone Medica Fund LP (and its companion VIMAC Milestone Medica Fund North LP for Canada), completed its initial closing on September 30, 2003, giving the team a cross-border U.S./Canada biotech and medical-device mandate. The team's model is to lead or co-lead a company's first institutional round, reserve capital for follow-on financings, and stay engaged through to a trade sale or IPO — with managers frequently taking seats on portfolio-company boards.
Investment Thesis & Focus
- Stage: Enters early — typically a company's first institutional round, structured as a Series A or Series B, with reserves to support subsequent rounds through exit.
- Sectors: Early-stage biotechnology, pharmaceuticals, and medical devices (life sciences only for Marcus's team).
- Check / commitment size: Roughly $5M–$15M per company across the investment's lifetime, including follow-on reserves.
- Ownership & involvement: Prefers to lead or co-lead deals and take an active governance role — VIMAC managers "play a very active role on portfolio companies' Boards of Directors."
- Geography: U.S. and Canada, run out of Boston.
- What makes them say yes: A fundable early-stage life-sciences company where VIMAC can anchor the first institutional round, add board-level value, and back it through follow-on financings to a trade sale or IPO.
Notable Investments
- Rapid Micro Biosystems — Bedford, MA maker of the Growth Direct automated microbial-detection system; VIMAC Milestone Medica Fund participated in the ~$18.6M Series A (2009, alongside Kleiner Perkins, TVM Capital, and Quaker BioVentures). The company IPO'd on NASDAQ in July 2021 at roughly an $800M valuation.
- Fennec Pharmaceuticals — specialty pharma company; listed publicly (Toronto Stock Exchange), a VIMAC portfolio exit.
- ViRexX Medical Corp. — Canadian biotech developer of immunotherapy/medical products; a VIMAC-associated life-sciences holding (referenced in SEC filings).
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.